NewAmsterdam Takes Another Step Toward CETP Inhibitor Success
Executive Summary
Positive Phase II data indicate that obicetrapib, a cholesterol-lowering drug licensed from Amgen, could succeed where prior drugs in the class have consistently failed for more than a decade.
You may also be interested in...
Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.